Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer
Background: Three different tyrosine kinase inhibitors have been approved as first-line therapies for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer with similar overall survival. This study determined dynamic changes in quality of life (QoL) for patien...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2018-02-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/1758834018755072 |
| _version_ | 1818300693389246464 |
|---|---|
| author | Szu-Chun Yang Chien-Chung Lin Wu-Wei Lai Sheng-Mao Chang Jing-Shiang Hwang Wu-Chou Su Jung-Der Wang |
| author_facet | Szu-Chun Yang Chien-Chung Lin Wu-Wei Lai Sheng-Mao Chang Jing-Shiang Hwang Wu-Chou Su Jung-Der Wang |
| author_sort | Szu-Chun Yang |
| collection | DOAJ |
| description | Background: Three different tyrosine kinase inhibitors have been approved as first-line therapies for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer with similar overall survival. This study determined dynamic changes in quality of life (QoL) for patients using these therapies after controlling for potential confounders. Methods: From 2011 to 2016, we prospectively assessed the utility values and QoL scores of patients using the EuroQol five-dimension and World Health Organization Quality-of-Life – Brief questionnaires. QoL functions after initiation of treatment were estimated using a kernel-smoothing method. Dynamic changes in major determinants were repeatedly assessed for constructing mixed models. Results: A total of 344 patients were enrolled, with 934 repeated assessments. After controlling for performance status, disease progression, EGFR mutation subtype and other confounders, the mixed models showed significantly lower QoL scores for afatinib versus gefitinib in the physical, psychological and social domains, and 10 facets. The differences seemed to appear 10 months after initiation of treatment. In contrast, there was no significant difference between erlotinib and gefitinib in the scores of all domains and facets. Conclusion: QoL in patients receiving afatinib seemed to be lower than in those receiving gefitinib. Since the sample sizes in this study were relatively small, more studies are warranted to corroborate these results. |
| first_indexed | 2024-12-13T05:11:10Z |
| format | Article |
| id | doaj.art-ab45b19a227f42139d234b76c8ce4500 |
| institution | Directory Open Access Journal |
| issn | 1758-8359 |
| language | English |
| last_indexed | 2024-12-13T05:11:10Z |
| publishDate | 2018-02-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj.art-ab45b19a227f42139d234b76c8ce45002022-12-21T23:58:32ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592018-02-011010.1177/1758834018755072Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancerSzu-Chun YangChien-Chung LinWu-Wei LaiSheng-Mao ChangJing-Shiang HwangWu-Chou SuJung-Der WangBackground: Three different tyrosine kinase inhibitors have been approved as first-line therapies for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer with similar overall survival. This study determined dynamic changes in quality of life (QoL) for patients using these therapies after controlling for potential confounders. Methods: From 2011 to 2016, we prospectively assessed the utility values and QoL scores of patients using the EuroQol five-dimension and World Health Organization Quality-of-Life – Brief questionnaires. QoL functions after initiation of treatment were estimated using a kernel-smoothing method. Dynamic changes in major determinants were repeatedly assessed for constructing mixed models. Results: A total of 344 patients were enrolled, with 934 repeated assessments. After controlling for performance status, disease progression, EGFR mutation subtype and other confounders, the mixed models showed significantly lower QoL scores for afatinib versus gefitinib in the physical, psychological and social domains, and 10 facets. The differences seemed to appear 10 months after initiation of treatment. In contrast, there was no significant difference between erlotinib and gefitinib in the scores of all domains and facets. Conclusion: QoL in patients receiving afatinib seemed to be lower than in those receiving gefitinib. Since the sample sizes in this study were relatively small, more studies are warranted to corroborate these results.https://doi.org/10.1177/1758834018755072 |
| spellingShingle | Szu-Chun Yang Chien-Chung Lin Wu-Wei Lai Sheng-Mao Chang Jing-Shiang Hwang Wu-Chou Su Jung-Der Wang Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer Therapeutic Advances in Medical Oncology |
| title | Dynamic changes in quality of life after three first-line therapies for EGFR
mutation-positive advanced non-small-cell lung cancer |
| title_full | Dynamic changes in quality of life after three first-line therapies for EGFR
mutation-positive advanced non-small-cell lung cancer |
| title_fullStr | Dynamic changes in quality of life after three first-line therapies for EGFR
mutation-positive advanced non-small-cell lung cancer |
| title_full_unstemmed | Dynamic changes in quality of life after three first-line therapies for EGFR
mutation-positive advanced non-small-cell lung cancer |
| title_short | Dynamic changes in quality of life after three first-line therapies for EGFR
mutation-positive advanced non-small-cell lung cancer |
| title_sort | dynamic changes in quality of life after three first line therapies for egfr mutation positive advanced non small cell lung cancer |
| url | https://doi.org/10.1177/1758834018755072 |
| work_keys_str_mv | AT szuchunyang dynamicchangesinqualityoflifeafterthreefirstlinetherapiesforegfrmutationpositiveadvancednonsmallcelllungcancer AT chienchunglin dynamicchangesinqualityoflifeafterthreefirstlinetherapiesforegfrmutationpositiveadvancednonsmallcelllungcancer AT wuweilai dynamicchangesinqualityoflifeafterthreefirstlinetherapiesforegfrmutationpositiveadvancednonsmallcelllungcancer AT shengmaochang dynamicchangesinqualityoflifeafterthreefirstlinetherapiesforegfrmutationpositiveadvancednonsmallcelllungcancer AT jingshianghwang dynamicchangesinqualityoflifeafterthreefirstlinetherapiesforegfrmutationpositiveadvancednonsmallcelllungcancer AT wuchousu dynamicchangesinqualityoflifeafterthreefirstlinetherapiesforegfrmutationpositiveadvancednonsmallcelllungcancer AT jungderwang dynamicchangesinqualityoflifeafterthreefirstlinetherapiesforegfrmutationpositiveadvancednonsmallcelllungcancer |